Any day now MannKind (NASDAQ:MNKD), is expected to launch its lead product Afrezza, an inhalable form of insulin. The company’s founder and namesake, Alfred Mann, has invested almost $1 billion of his own money to bring this product to market. Nate Pile’s best idea for 2015 is to invest alongside this successful serial entrepreneur as Afrezza brings MannKind to fruition.
Hey, check out all the research scientist jobs. Post your resume today!
